PHARMACEUTICAL COMPETITIVE INTELLIGENCE & ADVISORY
Look beyond
the obvious.
A deeper, sharper reading of pharmaceutical competition.
OUR EXPERTISE
End-to-end intelligence. From evidence to recommendations.
WHAT WE DO
Competitive intelligence
What changed, and what actually matters?
Monitoring, congress coverage, landscapes and targeted deep dives.
Strategic analysis
How credible is the threat or competitor plan?
Scientific evidence, development feasibility, competitor incentives and market realities.
Focused advisory
What should our team do next?
A senior external perspective, considered options and recommended next steps.
WHO ARE WE FOR?
For pharma executives who want more from their budget.
Deeper insights.
Go beyond reporting findings to understanding what they mean for your business.
Stakeholder-ready decks.
Clearer storylines and more useful slides that are easier to present internally.
Independent thinking.
Analysis and recommendations from an experienced CI and strategy consultant.
BEYOND A GOOD ANSWER
AI can already give you a good answer. We go deeper.
Good answers are a starting point.
CompX goes further into the evidence, the implications, and the recommendation. That means testing the assumptions behind the prevailing view, weighing alternative scenarios and working through what each could mean for your strategic choices.
WHY COMPX
The person who understands the brief does the work.
WHAT THIS MEANS FOR YOU
Senior expertise, not just senior oversight.
CompX is founder-led, combining extensive CI experience, scientific training and strategic expertise. The same experienced specialist works directly across the engagement, considering the evidence in its commercial context, from the initial question through to recommended next steps.
THE PERSON BEHIND COMPX
A little about me.
WHO I AMI'm Roland Galgoczy, a biomedical PhD and competitive intelligence and strategy consultant. Over more than a decade, I've helped pharmaceutical teams assess competitive threats, evaluate opportunities, and make better-informed decisions across development, portfolio strategy, and launch preparation.
SELECTED IMPACTMy work spans competitor and pipeline assessments, portfolio decisions, clinical development strategy and launch planning, helping pharmaceutical teams assess risks, prioritise opportunities and focus investment. I have worked across rare diseases, haematology, oncology, ophthalmology, immunology, dermatology and CNS, as well as generics, biosimilars and medical devices.
STRATEGIC PERSPECTIVEMy strategic experience draws on years of studying strategy literature, established frameworks and best practices, as well as applying them to competitive, development and commercial questions. I like to sit with a difficult problem, explore the evidence thoroughly, test different explanations and work through possible responses before settling on a recommendation.
LET'S TALK
Have a competitive question in mind?
Tell us what you're trying to understand. We'll start with the question.
YOUR NEXT STEP